PortfoliosLab logoPortfoliosLab logo
CRL vs. ILMN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CRL vs. ILMN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Charles River Laboratories International, Inc. (CRL) and Illumina, Inc. (ILMN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CRL achieves a -9.83% return, which is significantly lower than ILMN's 30.32% return. Over the past 10 years, CRL has outperformed ILMN with an annualized return of 7.68%, while ILMN has yielded a comparatively lower 1.90% annualized return.


CRL

1D
2.91%
1M
4.38%
YTD
-9.83%
6M
-2.60%
1Y
29.88%
3Y*
-3.58%
5Y*
-11.79%
10Y*
7.68%

ILMN

1D
5.16%
1M
22.64%
YTD
30.32%
6M
33.59%
1Y
108.88%
3Y*
-5.36%
5Y*
-15.92%
10Y*
1.90%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CRL vs. ILMN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CRL
Charles River Laboratories International, Inc.
-9.83%8.06%-21.91%8.49%-42.17%50.80%63.56%34.97%3.41%43.65%
ILMN
Illumina, Inc.
30.32%-1.85%-1.34%-31.14%-46.85%2.82%11.53%10.61%37.27%70.64%

Correlation

The correlation between CRL and ILMN is 0.53, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.53

Correlation (3Y)
Calculated over the trailing 3-year period

0.52

Correlation (5Y)
Calculated over the trailing 5-year period

0.53

Correlation (10Y)
Calculated over the trailing 10-year period

0.53

Correlation (All Time)
Calculated using the full available price history since Jul 31, 2000

0.39

The correlation between CRL and ILMN shifts across timeframes, from 0.39 (all time) to 0.53 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

CRL:

$8.80B

ILMN:

$26.32B

EPS

CRL:

-$3.75

ILMN:

$5.48

PS Ratio

CRL:

2.20

ILMN:

6.06

PB Ratio

CRL:

2.99

ILMN:

8.69

Total Revenue (TTM)

CRL:

$4.03B

ILMN:

$4.39B

Gross Profit (TTM)

CRL:

$1.00B

ILMN:

$2.93B

EBITDA (TTM)

CRL:

$737.05M

ILMN:

$1.39B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CRL vs. ILMN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRL
CRL Risk / Return Rank: 5959
Overall Rank
CRL Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
CRL Sortino Ratio Rank: 5757
Sortino Ratio Rank
CRL Omega Ratio Rank: 5858
Omega Ratio Rank
CRL Calmar Ratio Rank: 5959
Calmar Ratio Rank
CRL Martin Ratio Rank: 5858
Martin Ratio Rank

ILMN
ILMN Risk / Return Rank: 8888
Overall Rank
ILMN Sharpe Ratio Rank: 9090
Sharpe Ratio Rank
ILMN Sortino Ratio Rank: 9090
Sortino Ratio Rank
ILMN Omega Ratio Rank: 8787
Omega Ratio Rank
ILMN Calmar Ratio Rank: 8888
Calmar Ratio Rank
ILMN Martin Ratio Rank: 8686
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRL vs. ILMN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Charles River Laboratories International, Inc. (CRL) and Illumina, Inc. (ILMN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CRLILMNDifference
Sharpe ratioReturn per unit of total volatility

-1.67

Sortino ratioReturn per unit of downside risk

-2.10

Omega ratioGain probability vs. loss probability

1.15

1.39

-0.24

Calmar ratioReturn relative to maximum drawdown

0.89

4.27

-3.38

Martin ratioReturn relative to average drawdown

1.85

9.67

-7.83

CRL vs. ILMN - Sharpe Ratio Comparison

The current CRL Sharpe Ratio is 0.67, which is lower than the ILMN Sharpe Ratio of 2.33. The chart below compares the historical Sharpe Ratios of CRL and ILMN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CRLILMNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.67

2.33

-1.67

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.28

-0.35

+0.07

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.20

0.05

+0.16

Sharpe Ratio (All Time)

Calculated using the full available price history

0.24

0.16

+0.08

Drawdowns

CRL vs. ILMN - Drawdown Comparison

The maximum CRL drawdown since its inception was -78.23%, smaller than the maximum ILMN drawdown of -96.14%. Use the drawdown chart below to compare losses from any high point for CRL and ILMN.


Loading charts...

Drawdown Indicators


CRLILMNDifference

Max Drawdown

Largest peak-to-trough decline

-78.23%

-96.14%

+17.91%

Max Drawdown (1Y)

Largest decline over 1 year

-33.88%

-25.66%

-8.22%

Max Drawdown (3Y)

Largest decline over 3 years

-63.52%

-65.68%

+2.16%

Max Drawdown (5Y)

Largest decline over 5 years

-78.23%

-86.23%

+8.00%

Max Drawdown (10Y)

Largest decline over 10 years

-78.23%

-86.23%

+8.00%

Current Drawdown

Current decline from peak

-60.75%

-66.52%

+5.77%

Average Drawdown

Average peak-to-trough decline

-25.72%

-40.37%

+14.65%

Ulcer Index

Depth and duration of drawdowns from previous peaks

16.23%

11.30%

+4.93%

Volatility

CRL vs. ILMN - Volatility Comparison

Charles River Laboratories International, Inc. (CRL) has a higher volatility of 17.68% compared to Illumina, Inc. (ILMN) at 9.58%. This indicates that CRL's price experiences larger fluctuations and is considered to be riskier than ILMN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CRLILMNDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.68%

9.58%

+8.10%

Volatility (6M)

Calculated over the trailing 6-month period

34.98%

29.23%

+5.75%

Volatility (1Y)

Calculated over the trailing 1-year period

44.98%

46.92%

-1.94%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

42.71%

45.66%

-2.95%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

37.74%

42.17%

-4.43%

Dividends

CRL vs. ILMN - Dividend Comparison

Neither CRL nor ILMN has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CRL vs. ILMN - Financials Comparison

This section allows you to compare key financial metrics between Charles River Laboratories International, Inc. and Illumina, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


800.00M900.00M1.00B1.10B1.20B20222023202420252026
995.83M
1.09B
(CRL) Total Revenue
(ILMN) Total Revenue
Values in USD except per share items

CRL vs. ILMN - Profitability Comparison

The chart below illustrates the profitability comparison between Charles River Laboratories International, Inc. and Illumina, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%202220232024202520260
66.1%
Portfolio components
CRL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Charles River Laboratories International, Inc. reported a gross profit of 0.00 and revenue of 995.83M. Therefore, the gross margin over that period was 0.0%.

ILMN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Illumina, Inc. reported a gross profit of 721.00M and revenue of 1.09B. Therefore, the gross margin over that period was 66.1%.

CRL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Charles River Laboratories International, Inc. reported an operating income of 119.90M and revenue of 995.83M, resulting in an operating margin of 12.0%.

ILMN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Illumina, Inc. reported an operating income of 209.00M and revenue of 1.09B, resulting in an operating margin of 19.2%.

CRL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Charles River Laboratories International, Inc. reported a net income of -14.84M and revenue of 995.83M, resulting in a net margin of -1.5%.

ILMN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Illumina, Inc. reported a net income of 134.00M and revenue of 1.09B, resulting in a net margin of 12.3%.


Frequently Asked Questions


CRL and ILMN have a correlation of 0.53, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CRL has higher volatility (17.68%) compared to ILMN (9.58%). In terms of maximum drawdown, CRL dropped -78.23% vs ILMN's -96.14%.

ILMN currently has the higher Sharpe Ratio (2.33 vs 0.67), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CRL and ILMN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer